Immunovant, INC Form 4 insider transactions

Immunovant's Chief Financial Officer, Tiago Girao, acquired stock options and restricted stock units (RSUs) on April 7, 2026, as detailed in a Form 4 filing.

Immunovant CEO Eric Venker has settled a significant number of capped value appreciation rights (CVARs) into common stock and subsequently sold a portion to cover tax obligations.

Immunovant's Chief Legal Officer, Christopher Van Tuyl, sold 2,877 shares of common stock to cover tax withholding obligations related to RSU vesting.

Immunovant's Chief Operating Officer, Melanie Gloria, sold 3,238 shares of common stock to cover tax withholding obligations related to RSU vesting.

Immunovant's Chief Technology Officer, Jay S Stout, sold 1,977 shares of common stock to cover tax withholding obligations related to RSU vesting.

Immunovant's Chief Technology Officer, Jay S. Stout, sold 1,203 shares of common stock to cover tax withholding obligations related to RSU vesting.

Immunovant's Chief Legal Officer, Christopher Van Tuyl, sold 10,813 shares of common stock to cover tax withholding obligations related to RSU vesting.

Roivant Sciences Ltd. reported a significant acquisition of Immunovant, Inc. common stock, increasing its beneficial ownership to over 113 million shares.

Immunovant Director Andrew J. Fromkin sold common stock totaling 22,249 shares to cover tax obligations from restricted stock unit vesting.

Immunovant Director Douglas J. Hughes sold 15,000 shares of common stock in a pre-planned transaction to cover tax obligations from restricted stock unit vesting.

Immunovant's Chief Operating Officer, Melanie Gloria, sold 12,626 shares of common stock to cover tax withholding obligations related to RSU vesting.

Immunovant's Chief Medical Officer, Michael Geffner, sold 2,595 shares of common stock to cover tax withholding obligations related to RSU vesting.

Immunovant's Chief Technology Officer, Jay S. Stout, sold 2,520 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Immunovant's Chief Medical Officer, Michael Geffner, sold 1,272 shares of common stock to cover tax withholding obligations related to RSU vesting.

Immunovant's Chief Technology Officer, Jay S. Stout, sold 1,585 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Immunovant, Inc. Chief Executive Officer Eric Venker received substantial stock options and Capped Value Appreciation Rights as part of his compensation, aligning his incentives with shareholder value.

Immunovant's Chief Technology Officer, Jay S. Stout, sold 2,805 shares of common stock at $18.15 per share to satisfy tax withholding obligations related to the vesting of restricted stock units.

Immunovant's Chief Medical Officer, Michael Geffner, sold 2,385 shares of common stock at $18.15 per share to satisfy tax withholding obligations related to the vesting of restricted stock units.

Immunovant's Chief Medical Officer, Michael Geffner, sold 1,160 shares of common stock at a weighted average price of $17.24 per share to satisfy tax withholding obligations related to RSU vesting.

Immunovant, Inc.'s Chief Technology Officer, Jay S. Stout, sold 1,519 shares of common stock on July 9, 2025, at a weighted average price of $17.24 per share, to satisfy tax withholding obligations related to RSU vesting.

Tiago Girao, CFO of Immunovant, Inc., reports the acquisition of restricted stock units and stock options.

Director Jake Bauer received stock options and restricted stock units from Immunovant, Inc. on May 1, 2025, according to a Form 4 filing.

Director Robert Graham Susman reports the acquisition of restricted stock units and stock options in Immunovant, Inc.

Jay S. Stout, Chief Technology Officer of Immunovant, Inc., sold 1,925 shares of common stock on April 23, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Michael Geffner, Immunovant's Chief Medical Officer, sold 2,349 shares of common stock on April 23, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Eva Renee Barnett, CFO of Immunovant, Inc., sold 2,993 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Immunovant CEO Peter Salzmann sold 8,321 shares of common stock on April 16, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Jay S. Stout, Chief Technology Officer of Immunovant, Inc., sold 5,004 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Michael Geffner, Immunovant's Chief Medical Officer, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Eva Renee Barnett, CFO of Immunovant, Inc., sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units (RSUs).